Scientific Sessions 2025  /  Groundbreaking Trials in Cardiometabolic Therapeutics  /  The Next Era in Cardiometabolic Treatment
Logo

American Heart Association

  119
  0

Final ID:

The Next Era in Cardiometabolic Treatment

  • Ballantyne, Christie  ( BAYLOR COLLEGE MEDICINE , Houston , Texas , United States )
    • Author Disclosures:
    Christie Ballantyne: DO have relevant financial relationships ; Researcher:merck:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Researcher:Novo Nordisk:Active (exists now) ; Consultant:Arrowhead:Active (exists now) ; Researcher:Arrowhead:Active (exists now) ; Consultant:Ionis:Active (exists now) ; Researcher:Ionis:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Researcher:Amgen:Active (exists now) ; Consultant:Eli Lilly:Active (exists now) ; Researcher:Eli Lilly:Active (exists now) ; Consultant:Novartis:Active (exists now) ; Researcher:Novartis:Active (exists now) ; Consultant:Merck:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Groundbreaking Trials in Cardiometabolic Therapeutics

Saturday, 11/08/2025 , 08:30AM - 09:45AM

Late-Breaking Science

More abstracts on this topic:
Discussant

Lingvay Ildiko, Rosenson Robert

First-in-Human Phase 1 Clinical Trial of a CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3

Nicholls Stephen, Patel Naimish, Duran Jason, Nissen Steven, Laffin Luke, Scott Russell, Clifton Peter, Baker John, Sarraju Ashish, Singh Shweta, Xu Huansheng, Nielsen Jennifer

More abstracts from these authors:
Will apoCIII therapies tip the BALANCE towards targeting triglycerides?

Tsimikas Sotirios, Ballantyne Christie

Targets, Tools, and Tailored Therapy: What's New and What's Next in Lipid Management for Coronary Atherosclerosis

Ballantyne Christie

You have to be authorized to contact abstract author. Please, Login
Not Available